- Adj. EBITA SEK 215m (-3% vs. ABGSCe 222m) - Consensus full-year EBITA likely down marginally - 12x...
Q-linea and its distribution partners continue to advance pilot and tender process activities, which...
Redeye provides its initial take on Lifco’s Q2 2024 report, which came in broadly above our estimate...
Redeye updates its estimates ahead of Arise’s Q2 report, which is due on 17 July.
Ascelia proceeds with a rights issue of units to secure growth capital to be able to finalize and su...
Redeye returns following IRLAB's Q2 report and recent clinical progress.
Det höga ränteläget fortsätter att påverka förvaltningsresultatet negativt, men väntas förbättras i ...
Redeye leaves a short comment following Kancera's announcement from earlier this morning regarding c...
- We cut '24e-'26e ARR by 2-3% on continued macro weakness - Still awaiting a return in B2C business...
- We cut '25e-'26e EBIT by 2%... - ...and still expect no organic growth in '24e - Trading at NTM EV...
- FTX claim sold and FlowBank investment impaired - We increase adj.
Redeye provides a research update following the Q3 report recently published by Newbury.
EU-lagen CRMA (European Critical Raw Materials Act) har blivit godkänd och gäller från och med mars ...
- Q2'24 results due 22 July - 24e-'26e EBIT revised down 1.
Det höga ränteläget fortsätter att påverka förvaltningsresultatet negativt, som sjönk med 6% på årsb...
